According to GlobalData, while the majority of the 22 vaccine candidates currently in development rely on traditional ...

RNA vaccines have gained widespread attention for their crucial role in fighting the COVID-19 pandemic. Yet, even before the ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

A German study published in July 2024 did not find that mRNA COVID-19 vaccines damaged children’s immune systems, contrary to ...

Even as the Covid wave in Florida continues, Gov. Ron DeSantis’ administration is once again advising against the mRNA ...

Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use..." ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) yesterday and set a ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

As of 1:44 pm GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

Primrose Bio, a San Diego biotech company, has begun a partnership to jointly develop and market products for mRNA medicines.

Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...

As of 19 September at 1:23 pm GMT-4. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.